'Substantially increased' risk of intracranial haemorrhage with higher-dose rivaroxaban

NOACs compared with aspirin

Higher doses of rivaroxaban increase patients' risk of intracranial haemorrhage compared with aspirin, whereas lower doses of rivaroxaban and apixaban do not, according to a systematic review and meta-analysis.

"Non-vitamin K antagonist oral anticoagulants (NOACs) are not all the same," said co-author Dr Meng Lee from Chang Gung University College of Medicine, Puzi, Taiwan.

"Rivaroxaban 15-20 mg once daily substantially increased the risks of